Senior Director, Program Management (Biotechnology)

Location: Waltham, Massachusetts, United States; onsite with no possibility of remote work

Salary: $233,000–$285,000 USD base pay annually

Company

hirify.global develops therapeutics targeting muscle and the central nervous system to treat genetically driven neuromuscular diseases.

What you will do

• Lead one or more cross-functional development teams and drive execution against program priorities, goals, and resources.
• Partner with Program Team Leaders and subject matter experts to establish short-, medium-, and long-term priorities.
• Develop and maintain Target Product Profiles, Clinical Development Plans, Regulatory Strategies, Supply Strategies, and integrated program plans.
• Align non-clinical, clinical, regulatory, and commercialization strategies with overall program objectives.
• Facilitate timely, data-driven decisions across governance forums, senior leadership, external experts, and program stakeholders.
• Advance program management practices while supporting research and development in muscle diseases and oligonucleotide therapeutics.

Requirements

• Bachelor’s degree in science or a related field.
• 15+ years of relevant biotechnology or pharmaceutical industry experience with increasing responsibility in drug development.
• Experience with late-stage clinical development and commercial-stage programs is required.
• Expertise in cross-functional teamwork, influencing without direct authority, and guiding complex, high-stakes decisions.
• Exceptional verbal, written, and presentation communication skills.
• Proficiency with Microsoft Office 365, Smartsheet, and project management collaboration tools.

Nice to have

• Advanced scientific degree or MBA.
• Experience with neuromuscular diseases.

Culture & Benefits

• Onsite role in Waltham, Massachusetts.
• Fast-paced, patient-focused, results-driven environment.
• Emphasis on collaboration, innovation, scientific excellence, open communication, and continual improvement.
• Opportunity to contribute to a growing portfolio of disease products.